| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $82,561,065 | 5 | 19 |
Sells | $17,090,740 | 22 | 81 |
| RA CAPITAL MANAGEMENT, L.P. | 4 | $54.63M | 0 | $0 | $54.63M | |
| GSK plc | 10 percent owner | 1 | $27.93M | 0 | $0 | $27.93M |
| TAKANASHI KEN | director | 0 | $0 | 1 | $23,223 | $-23,223 |
| Vargeese Chandra | See Remarks | 0 | $0 | 1 | $43,417 | $-43,417 |
| BOLNO PAUL | President and CEO | 0 | $0 | 1 | $140,956 | $-140,956 |
| CORRIGAN MARK | director | 0 | $0 | 1 | $217,297 | $-217,297 |
| Wagner Heidi L | director | 0 | $0 | 2 | $231,070 | $-231,070 |
| Verdine Gregory L. | director | 0 | $0 | 1 | $269,461 | $-269,461 |
| Rawcliffe Adrian | director | 0 | $0 | 3 | $806,604 | $-806,604 |
| Tan Aik Na | director | 0 | $0 | 2 | $1.19M | $-1.19M |
| HENRY CHRISTIAN O | director | 0 | $0 | 1 | $1.29M | $-1.29M |
| Moran Kyle | Chief Financial Officer | 0 | $0 | 4 | $4.36M | $-4.36M |
| Francis Chris | See Remarks | 0 | $0 | 5 | $8.52M | $-8.52M |
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a …
Over the last 12 months, insiders at Wave Life Sciences Ltd. have bought $82.56M and sold $17.09M worth of Wave Life Sciences Ltd. stock.
On average, over the past 5 years, insiders at Wave Life Sciences Ltd. have bought $63.2M and sold $5.84M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $54.63M. GSK plc (10 percent owner) — $27.93M.
The last purchase of 971,091 shares for transaction amount of $6.31M was made by RA CAPITAL MANAGEMENT, L.P. () on 2026‑03‑30.
| 2026-08-12 | Sale | Rawcliffe Adrian | director | 12,700 0.0065% | $5.29 | $67,183 | -24.52% | |
| 2026-08-11 | Sale | Wagner Heidi L | director | 7,000 0.0042% | $6.01 | $42,070 | -21.58% | |
| 2026-08-11 | Sale | Tan Aik Na | director | 432 0.0003% | $6.01 | $2,596 | -21.58% | |
| 2026-08-11 | Sale | TAKANASHI KEN | director | 3,864 0.0023% | $6.01 | $23,223 | -21.58% | |
| 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. | 971,091 0.5065% | $6.50 | $6.31M | -12.69% | |||
| 2026-03-27 | RA CAPITAL MANAGEMENT, L.P. | 2.5M 1.3392% | $6.43 | $16.05M | -9.18% | |||
| 2026-03-26 | RA CAPITAL MANAGEMENT, L.P. | 5.31M 2.7644% | $6.08 | $32.27M | -6.61% | |||
| 2026-02-26 | Sale | Francis Chris | See Remarks | 33,194 0.0178% | $15.05 | $499,593 | -61.52% | |
| 2026-02-09 | Sale | Vargeese Chandra | See Remarks | 3,228 0.0017% | $13.45 | $43,417 | -56.11% | |
| 2026-02-09 | Sale | BOLNO PAUL | President and CEO | 10,480 0.0056% | $13.45 | $140,956 | -56.11% | |
| 2026-02-09 | Sale | Moran Kyle | Chief Financial Officer | 3,588 0.0019% | $13.45 | $48,259 | -56.11% | |
| 2026-02-09 | Sale | Francis Chris | See Remarks | 1,883 0.001% | $13.45 | $25,326 | -56.11% | |
| 2026-01-02 | Sale | Francis Chris | See Remarks | 9,375 0.0054% | $16.03 | $150,260 | -61.00% | |
| 2025-12-11 | GSK plc | 10 percent owner | 1.47M 1.0173% | $19.00 | $27.93M | -62.06% | ||
| 2025-12-09 | Sale | Moran Kyle | Chief Financial Officer | 50,000 0.0286% | $20.02 | $1M | -70.08% | |
| 2025-12-09 | Sale | Moran Kyle | Chief Financial Officer | 50,036 0.0287% | $20.03 | $1M | -70.08% | |
| 2025-12-08 | Sale | Verdine Gregory L. | director | 20,000 0.0089% | $13.47 | $269,461 | -65.55% | |
| 2025-12-08 | Sale | Moran Kyle | Chief Financial Officer | 150,000 0.0761% | $15.40 | $2.31M | -65.55% | |
| 2025-12-08 | Sale | Wagner Heidi L | director | 14,000 0.0062% | $13.50 | $189,000 | -65.55% | |
| 2025-12-08 | Sale | CORRIGAN MARK | director | 16,115 0.0072% | $13.48 | $217,297 | -65.55% |
| RA CAPITAL MANAGEMENT, L.P. | 26975505 13.6773% | $96.57M | 10 | 0 | +45.44% | |
| GSK plc | 10 percent owner | 18245691 9.251% | $65.32M | 3 | 0 | +14.41% |
| TAKANASHI KEN | director | 20079 0.0102% | $71,882.82 | 2 | 2 | +2.01% |
| Tanaka Masaharu | 2774118 1.4065% | $9.93M | 2 | 3 | +2.01% |
$100,473,344 | 83 | 9.53% | $826.91M | |
$860,541,348 | 82 | -5.10% | $649.64M | |
$1,108,102,085 | 66 | 36.91% | $755.04M | |
$59,156,363 | 22 | 29.25% | $686.5M | |
$22,365,077 | 19 | -27.47% | $674.89M |
| Increased Positions | 153 | +76.5% | 64M | +44.77% |
| Decreased Positions | 90 | -45% | 25M | -17.33% |
| New Positions | 73 | New | 36M | New |
| Sold Out Positions | 41 | Sold Out | 9M | Sold Out |
| Total Postitions | 263 | +31.5% | 181M | +27.43% |
| Ra Capital Management, L.P. | $290,322.00 | 9.95% | 18.2M | 0 | 0% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $232,356.00 | 7.96% | 14.57M | -448,716 | -2.99% | 2025-09-30 |
| Blackrock, Inc. | $166,371.00 | 5.7% | 10.43M | +47,097 | +0.45% | 2025-09-30 |
| Maverick Capital Ltd | $133,850.00 | 4.59% | 8.39M | +130,173 | +1.58% | 2025-09-30 |
| Driehaus Capital Management Llc | $100,454.00 | 3.44% | 6.3M | -233,459 | -3.57% | 2025-09-30 |
| M28 Capital Management Lp | $90,350.00 | 3.1% | 5.66M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $81,829.00 | 2.8% | 5.13M | +5M | +728.63% | 2025-09-30 |
| Kynam Capital Management, Lp | $72,733.00 | 2.49% | 4.56M | 0 | 0% | 2025-09-30 |
| 683 Capital Management, Llc | $66,193.00 | 2.27% | 4.15M | +50,000 | +1.22% | 2025-09-30 |
| Bellevue Group Ag | $65,307.00 | 2.24% | 4.09M | 0 | 0% | 2025-09-30 |